Extended-release viloxazine for children with ADHD makes good in phase III trial
14 Aug 2020
bởiJairia Dela Cruz
Once-daily treatment with viloxazine extended release, also known as SPN-812, is safe and effective in children aged 6–11 years with attention-deficit/hyperactivity disorder (ADHD), yielding rapid improvements in symptoms and function, according to the results of a phase III trial.